WASHINGTON, D.C. — Alabama Sens. Katie Britt and Tommy Tuberville have joined more than 100 Republican lawmakers in urging the U.S. Supreme Court to uphold a Louisiana-led bid to sharply restrict mail-order access to the abortion pill mifepristone, escalating what advocates say is a coordinated national attack on women’s reproductive rights.
In a May filing, Britt and Tuberville signed onto a bicameral amicus brief backing Louisiana v. FDA, a lawsuit that seeks to reinstate an in-person dispensing requirement for mifepristone nationwide. The brief, led by Sen. Bill Cassidy of Louisiana, argues that the Food and Drug Administration violated federal law when it allowed the abortion medication to be prescribed via telehealth and delivered by mail or pharmacy beginning in 2023.
Tuberville’s office said he joined the brief to support “protect[ing] women and their unborn children from dangerous mail-order chemical abortion drugs,” language that frames the case as a safety issue rather than a direct challenge to abortion rights. Britt, who has built a strongly anti-abortion voting record in the Senate while also stressing support for in vitro fertilization access, is listed among 28 Republican senators signing the brief.
The lawsuit, filed by Louisiana in October 2025, contends that the FDA’s telehealth and mail-order policy for mifepristone violated the Administrative Procedure Act and should be rolled back across all 50 states. Mifepristone, used in combination with misoprostol, is involved in most abortions in the United States and is also prescribed to manage early miscarriage.
Earlier this year, the Fifth U.S. Circuit Court of Appeals, based in New Orleans, sided with Louisiana and ordered that the drug could no longer be dispensed by mail, requiring patients to receive it in person at a clinic or medical office. On May 4, the Supreme Court issued a temporary administrative stay, allowing telehealth and mail-order access to continue while justices consider whether to block the Fifth Circuit’s ruling for the duration of the case.
Civil rights and reproductive health groups say the Louisiana case—and the amicus brief backed by Britt and Tuberville—aims to impose a single state’s anti-abortion agenda on the entire country, including states where abortion remains legal. The ACLU, the Center for Reproductive Rights and other advocates describe the in-person dispensing rule as “medically unnecessary,” arguing that cutting off mailed prescriptions would disproportionately harm low-income women, those in rural areas and patients who cannot easily travel for care.
Policy analysts note that medication abortion has become a key access point in the post-Roe landscape, with more than half of U.S. abortions now provided using pills and a growing share delivered via telemedicine and the mail. They warn that a Supreme Court ruling in Louisiana’s favor could ripple far beyond abortion, undermining FDA authority over drug safety and opening the door for future political challenges to other medications tied to reproductive and sexual health.
Britt and Tuberville have repeatedly pressed federal regulators on mifepristone, including a 2025 letter urging the Department of Health and Human Services and the FDA to reassess approval of a generic version of the drug. In that letter, the Alabama senators and their colleagues praised officials for questioning the pill’s safety and called for “decisive action” to revisit whether it should be allowed onto the market.
Their latest move to back Louisiana’s lawsuit places Alabama firmly in the camp of states and lawmakers seeking to force stricter abortion limits nationwide, even as the Trump administration and conservative state governments have already tightened access through bans and gestational limits. For women in Alabama, where abortion is already heavily restricted, advocates say the case could further narrow options for miscarriage management and out-of-state care if telehealth and mail-order services are curtailed across the country.
Reproductive rights organizations frame the fight over mifepristone as a bellwether for the broader struggle over bodily autonomy and health care access. They argue that the combination of Louisiana’s lawsuit, the Fifth Circuit’s ruling and the amicus campaign by senators like Britt and Tuberville represents an aggressive new front in efforts to restrict not only abortion, but the right of women to make private medical decisions without political interference.
As the Supreme Court weighs the Louisiana case and related challenges from mifepristone manufacturers, patients and providers are left navigating shifting rules and looming uncertainty. A ruling in favor of Louisiana and its allies could cement in-person-only access to abortion pills nationwide, advocates say, marking a major setback for women’s rights in Alabama and beyond.